Armbruster SD, et al. - Researchers examined clinicopathologic features in patients with early-stage uterine clear cell carcinoma (UCCC). In addition, they sought for adjuvant treatment effects on recurrence-free (RFS) and overall survival (OS). In this retrospective review, 112 women with confirmed stage I or II UCCC treated and/or followed between 2000 and 2016 were included. In majority, patients presented with mixed UCCC (61%) vs pure UCCC (39%). Stage IA UCCC (66%) vs stage IB (15%) or stage II (18%) disease was identified in the majority of patients. Chemotherapy + radiation (26%), brachytherapy (27%), whole pelvic radiation (15%), chemotherapy alone (8%), and observation (24%) were the included adjuvant treatment. For early-stage UCCC patients, OS approaches 10 years. they noted worse PFS and OS for women ≥70 years regardless of treatment modality, encouraging consideration of the quality of life implications when electing for adjuvant therapy.